MetaVia Q1 net loss $3.8M; Phase 1 Part 3 dosing started for DA-1726

MetaVia Inc.

2026-Q1 EPS reported -$0.79

Net loss of $3.8M ($0.79 per share) vs $3.7M ($3.93 per share) in Q1 2025.
Cash and cash equivalents $13.7M as of March 31, 2026, sufficient into Q4 2026.
First patient dosed in Phase 1 Part 3 16-week titration study of DA-1726; data expected Q4 2026.
January 2026 public offering raised ~$9.3M gross proceeds to fund operations.
R&D expenses $2.1M, G&A $1.9M; total operating expenses $4.0M.

item 2.02item 7.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.